Cubist to acquire Calixa

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) will acquire fellow infectious disease company Calixa Therapeutics Inc. (San Diego, Calif.) for $92.5 million in cash and up to $310 million in milestones. Cubist will gain CXA-101, a cephalosporin antibiotic in Phase II testing for complicated urinary tract infection (cUTI); and CXA-201, a combination of CXA-101 and beta lactamase (LACTB) inhibitor tazobactam, which is expected to begin Phase II testing for complicated intra-abdominal infections and cUTI in 1H10 and nosocomial pneumonia in 2H10. ...